Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EQL Pharma AB ( (SE:EQL) ) has shared an update.
EQL Pharma AB has announced that its key product, Mellozzan® (melatonin), has been approved for sale in Turkey by the Turkish Medicines Agency. The product will be manufactured and marketed locally by EQL’s partner, Abdi Ibrahim, with sales expected to begin in the first half of 2026. This approval marks a significant step for EQL Pharma’s expansion into new markets, potentially enhancing its market presence and providing new revenue streams. Additionally, there are plans to expand Mellozzan® with an oral solution in Turkey by 2027, and applications have been submitted for approval in Kazakhstan.
More about EQL Pharma AB
EQL Pharma AB is a company that specializes in developing and selling generic drugs, focusing on niche generics with limited competition. The company operates primarily in the Nordic and European markets, with a significant pipeline of products. EQL Pharma collaborates with leading contract manufacturers and pharmaceutical companies in the EU and Asia, and is listed on the Nasdaq Stockholm stock market.
Average Trading Volume: 31,146
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.55B
See more data about EQL stock on TipRanks’ Stock Analysis page.